Literature DB >> 7929177

Pathway-specific regulation of the synthesis of anticoagulantly active heparan sulfate.

N W Shworak1, M Shirakawa, S Colliec-Jouault, J Liu, R C Mulligan, L K Birinyi, R D Rosenberg.   

Abstract

L cells and endothelial cells synthesize a heparan sulfate (HS) subpopulation, HSact, that exhibits anticoagulant activity due to a specific monosaccharide sequence; the remaining heparan sulfate, HSinact, lacks this region of defined structure and is anticoagulantly inactive. HSact biosynthesis was examined in these two cell types by stably expressing epitope-tagged rat ryudocan (ryudocan12CA5), which possesses three glycosaminoglycan (GAG) acceptor sites. Both HSact and HSinact were present on ryudocan12CA5 isolated from L cells and endothelial cells; thus, a core protein with a unique primary sequence initiates the synthesis of both GAGs. The expression in L cells of ryudocan12CA5 variants containing a single functional GAG acceptor site demonstrated that each of the three acceptor regions initiates the synthesis of both types of GAGs to a similar extent. Most importantly, in both cell types total HSact generation declined as a function of ryudocan12CA5 overexpression even though HSinact production increased linearly as a function of this variable. This discordant relationship is a general property of the biosynthetic machinery since in both cell types HSact production was reduced to an equal extent on protein cores of either exogenous or endogenous origins. The suppression of HSact generation was also observed with a secreted form of core protein lacking transmembrane and cytoplasmic domains or by a GAG acceptor site mutated form of core protein incapable of augmenting GAG synthesis. These results suggest that elevated intracellular levels of core protein saturate the capacity of a critical component of the HSact biosynthetic machinery. This critical component is not a member of the common set of biosynthetic enzymes involved in the production of HSact and HSinact since no structural changes were observed in either GAG during overexpression of core protein. Based upon the above data, we conclude that increased intracellular levels of ryudocan probably act by saturating the capacity of components which regulate HSact production by coordinating the function of biosynthetic enzymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929177

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 2.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

Authors:  R D Rosenberg; N W Shworak; J Liu; J J Schwartz; L Zhang
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

3.  Cholesterol-dependent changes of glycosaminoglycan pattern in human aorta.

Authors:  R Kruse; M Merten; K Yoshida; A Schmidt; W Völker; E Buddecke
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

4.  Portable sulphotransferase domain determines sequence specificity of heparan sulphate 3-O-sulphotransferases.

Authors:  T Yabe; D Shukla; P G Spear; R D Rosenberg; P H Seeberger; N W Shworak
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

Review 5.  Syndecans: multifunctional cell-surface co-receptors.

Authors:  D J Carey
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

Review 6.  Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.

Authors:  Nicholas W Shworak; Sassan HajMohammadi; Ariane I de Agostini; Robert D Rosenberg
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

7.  Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity.

Authors:  Ariane I de Agostini; Ji-Cui Dong; Corinne de Vantéry Arrighi; Marie-Andrée Ramus; Isabelle Dentand-Quadri; Sébastien Thalmann; Patricia Ventura; Victoria Ibecheole; Felicia Monge; Anne-Marie Fischer; Sassan HajMohammadi; Nicholas W Shworak; Lijuan Zhang; Zhenqing Zhang; Robert J Linhardt
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

8.  Hs3st3-modified heparan sulfate controls KIT+ progenitor expansion by regulating 3-O-sulfotransferases.

Authors:  Vaishali N Patel; Isabelle M A Lombaert; Samuel N Cowherd; Nicholas W Shworak; Yongmei Xu; Jian Liu; Matthew P Hoffman
Journal:  Dev Cell       Date:  2014-06-23       Impact factor: 12.270

9.  The principal neuronal gD-type 3-O-sulfotransferases and their products in central and peripheral nervous system tissues.

Authors:  Roger Lawrence; Tomio Yabe; Sassan Hajmohammadi; John Rhodes; Melissa McNeely; Jian Liu; Edward D Lamperti; Paul A Toselli; Miroslaw Lech; Patricia G Spear; Robert D Rosenberg; Nicholas W Shworak
Journal:  Matrix Biol       Date:  2007-03-30       Impact factor: 11.583

10.  Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican.

Authors:  R Steinfeld; H Van Den Berghe; G David
Journal:  J Cell Biol       Date:  1996-04       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.